NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) Given Average Rating of “Hold” by Brokerages

Shares of NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) have earned a consensus rating of “Hold” from the five analysts that are currently covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, one has issued a hold rating and three have assigned a buy rating to the company. The average 12-month price target among analysts that have covered the stock in the last year is $1.9833.

A number of research firms have commented on NMTC. Zacks Research cut shares of NeuroOne Medical Technologies from a “strong-buy” rating to a “hold” rating in a research report on Friday, March 13th. JonesTrading began coverage on shares of NeuroOne Medical Technologies in a research note on Monday, March 2nd. They issued a “buy” rating and a $1.50 price target on the stock. Finally, Wall Street Zen upgraded shares of NeuroOne Medical Technologies to a “sell” rating in a report on Saturday, February 21st.

NeuroOne Medical Technologies Stock Down 1.3%

NMTC stock opened at $0.76 on Friday. NeuroOne Medical Technologies has a 52-week low of $0.40 and a 52-week high of $1.16. The stock has a market cap of $38.41 million, a price-to-earnings ratio of -4.47 and a beta of 0.74. The business has a fifty day moving average of $0.79 and a two-hundred day moving average of $0.79.

NeuroOne Medical Technologies (NASDAQ:NMTC) last released its quarterly earnings results on Tuesday, February 17th. The company reported ($0.03) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.04) by $0.01. The business had revenue of $2.89 million during the quarter, compared to analysts’ expectations of $2.47 million. NeuroOne Medical Technologies had a negative return on equity of 119.92% and a negative net margin of 78.34%.

Insider Transactions at NeuroOne Medical Technologies

In other news, insider David J. Wambeke bought 1,000,000 shares of the business’s stock in a transaction on Sunday, March 1st. The shares were bought at an average price of $0.67 per share, with a total value of $670,000.00. Following the completion of the transaction, the insider directly owned 1,000,000 shares in the company, valued at $670,000. This trade represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders sold a total of 14,637 shares of company stock valued at $11,710 over the last 90 days. 11.80% of the stock is owned by insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the company. Sio Capital Management LLC acquired a new stake in shares of NeuroOne Medical Technologies in the second quarter valued at $2,390,000. Vanguard Group Inc. lifted its stake in NeuroOne Medical Technologies by 31.2% during the 3rd quarter. Vanguard Group Inc. now owns 1,578,237 shares of the company’s stock worth $1,403,000 after acquiring an additional 375,639 shares in the last quarter. Essex Investment Management Co. LLC purchased a new position in NeuroOne Medical Technologies during the 4th quarter valued at about $143,000. Virtu Financial LLC acquired a new position in NeuroOne Medical Technologies in the 3rd quarter valued at about $88,000. Finally, Goldman Sachs Group Inc. acquired a new position in NeuroOne Medical Technologies in the 1st quarter valued at about $84,000. 16.07% of the stock is currently owned by hedge funds and other institutional investors.

NeuroOne Medical Technologies Company Profile

NeuroOne Medical Technologies Corp. is a medical device company focused on developing advanced neural interface technologies for diagnostic and therapeutic applications in neurosurgery and neurology. The company’s core mission is to improve patient outcomes through next-generation electrode systems that enable high-resolution neural recording and targeted stimulation. By leveraging proprietary thin-film microelectrode arrays, NeuroOne aims to offer clinicians unprecedented single-unit precision during brain mapping procedures.

The company’s flagship platform, the EVO™ system, integrates thin-film neural electrodes with intraoperative monitoring hardware and software.